![]() |
市場調查報告書
商品編碼
1764875
歐洲器官保存解決方案市場預測(至 2031 年)- 區域分析 - 按產品、應用、類型和最終用戶Europe Organ Preservation Solution Market Forecast to 2031 - Regional Analysis - by Product, Application, Type, and End User |
2023 年歐洲器官保存液市場價值為 86,522.54 千美元,預計到 2031 年將達到 1,59,990.22 千美元;預計 2024 年至 2031 年的複合年成長率為 8.1%。
慢性病盛行率上升推動歐洲器官保存解決方案市場
慢性疾病,無論是先天性的還是後天性的,都會隨著時間的推移逐漸損害器官。慢性疾病通常不會自行痊癒,但或許有一些方法可以減緩其造成的傷害。這種損害可能需要數十年才能累積到明顯影響患者器官功能或需要醫療干預的程度。慢性腎臟病 (CKD) 是一種常見且可能致命的疾病,全球約有十分之一的人患有此病。脂肪肝和C型肝炎等慢性肝病是導致慢性肝衰竭的常見原因。世界衛生組織 (WHO) 估計,全球約有 5,000 萬人感染慢性C型肝炎病毒,每年約有 100 萬人新增感染病例。 2022 年,約有 24.2 萬人死於C型肝炎,主要原因是肝硬化和肝細胞癌。慢性心臟病,包括冠狀動脈疾病和先天性心臟病,可導致進行性心臟衰竭。根據英國心臟基金會發布的《全球心臟與循環系統疾病概況》,先天性心臟病是全球兒童健康中一個快速崛起的問題。全球每110個新生兒中約有1個被診斷出患有先天性心臟病,而嬰兒成年後確診的病例每年可能高達120萬例,平均每天3300例(即每26秒就有一例)。因此,隨著慢性疾病相關器官移植需求的激增,器官保存解決方案的需求也隨之增加。
歐洲器官保存解決方案市場概覽
歐洲器官保存解決方案市場細分為德國、法國、英國、西班牙、義大利和歐洲其他地區。預計在預測期內,德國和義大利將在區域市場中佔據相當大的市場佔有率。未來幾年,法國、英國和西班牙市場可能會迎來豐厚的利潤。器官移植數量的增加、導致器官衰竭的慢性病盛行率的上升以及器官保存解決方案的技術進步,推動了歐洲器官保存解決方案市場的成長。預計德國將成為全球器官保存解決方案市場成長的主要貢獻者之一。根據“世界人口老化”,2017年德國總人口中近28.0%為60歲及以上,預計到2050年老齡人口將上升到近37.6%。慢性病的盛行率隨著年齡的成長而增加。此外,隨著年齡的成長,許多器官開始出現故障或功能障礙,增加了對器官移植程序的需求。因此,隨著老年人口的增加,對器官保存解決方案的需求也日益成長。
歐洲器官保存解決方案市場收入及預測(2031年)(千美元)
歐洲器官保存解決方案市場細分
歐洲器官保存解決方案市場按產品、應用、類型、最終用戶和國家分類。
根據產品類型,歐洲器官保存液市場分為威斯康辛大學溶液、custodiol HTK、Perfadex、HypoThermosol 等。威斯康辛大學溶液在2023年佔據了最大的市場佔有率。
從應用角度來看,歐洲器官保存液市場細分為靜態冷藏、低溫機械灌注、常溫機械灌注等。靜態冷藏領域在2023年佔據了最大的市場。
依類型分類,歐洲器官保存液市場分為腎臟、肝臟、肺臟、心臟和其他器官。腎臟器官在2023年佔據了最大的市場。
根據最終用戶,歐洲器官保存解決方案市場細分為器官移植中心、醫院和專科診所。器官移植中心在2023年佔據了最大的市場。
依國家/地區分類,歐洲器官保存液市場分為英國、德國、法國、義大利、西班牙和歐洲其他地區。 2023年,德國佔據了歐洲器官保存液市場佔有率的主導地位。
XVIVO Perfusion、TransMedics、OrganOx Limited、Paragonix Technologies, Inc、Dr. Franz Koehler Chemie GmbH 和 Accord Healthcare 是歐洲器官保存解決方案市場領先的公司。
The Europe organ preservation solution market was valued at US$ 86,522.54 thousand in 2023 and is expected to reach US$ 1,59,990.22 thousand by 2031; it is estimated to register a CAGR of 8.1% from 2024 to 2031.
Increasing Prevalence of Chronic Disease Fuels Europe Organ Preservation Solution Market
Chronic diseases, which may be congenital or acquired, can lead to gradual damage to organs over time. A chronic disease typically does not resolve on its own, but there may be ways to slow down the damage caused by the condition. It may take decades for this damage to build up to the point where it noticeably affects patients' organ function or requires medical intervention. Chronic kidney disease (CKD) is a common and potentially fatal condition that affects approximately 1 in every 10 people worldwide. Chronic liver diseases such as fatty liver disease and hepatitis C are the common causes of chronic liver failure. The World Health Organization (WHO) estimates that ~50 million people are living with chronic hepatitis C virus infection worldwide, with approximately 1.0 million new infections occurring each year. In 2022, ~242,000 people died from hepatitis C, mainly due to cirrhosis and hepatocellular carcinoma. Chronic heart diseases, including coronary artery disease and congenital heart disease, can lead to progressive heart failure. According to the Global Heart & Circulatory Diseases Factsheet by the British Heart Foundation, congenital heart disease is a rapidly emerging problem in child health worldwide. It is diagnosed in approximately 1 in 110 births globally, and the diagnoses later in the lives of babies may reach as high as 1.2 million per year, averaging 3,300 per day (or a diagnosis every 26 seconds). Thus, the demand for organ preservation solutions increases with a surge in the need for availability of chronic disease-related organ transplantation procedures.
Europe Organ Preservation Solution Market Overview
The Europe organ preservation solution market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Germany and Italy are expected to account for a significant market share in the regional market during the forecast period. The market in France, the UK, and Spain is likely to experience lucrative opportunities in the coming years. The growing number of organ transplantations, rising prevalence of chronic diseases that lead to organ failure, and technological advancements in organ preservation solutions drive the organ preservation solution market growth in Europe. Germany is expected to be among the major contributors to the growth of the organ preservation solution market in worldwide. As per the "World Population Ageing," nearly 28.0% of the total population of Germany was aged 60 and above in 2017, and the aging population is estimated to rise to nearly 37.6% by 2050. The prevalence of chronic diseases increases with age. Also, with growing age, many organs start to malfunction or become dysfunctional, giving rise to the demand for organ transplantation procedures. Thus, with the rising geriatric population, the demand for organ preservation solutions is growing.
Europe Organ Preservation Solution Market Revenue and Forecast to 2031 (US$ Thousand)
Europe Organ Preservation Solution Market Segmentation
The Europe organ preservation solution market is categorized into product, application, type, end user, and country.
Based on product, the Europe organ preservation solution market is categorized into University of Wisconsin solution, custodiol HTK, Perfadex, HypoThermosol, and others. The University of Wisconsin segment held the largest market share in 2023.
In terms of application, the Europe organ preservation solution market is segmented into static cold storage, hypothermic machine perfusion, normothermic machine perfusion, and others. The static cold storage segment held the largest market share in 2023.
By type, the Europe organ preservation solution market is categorized into kidneys, liver, lungs, heart, and others. The kidneys segment held the largest market share in 2023.
Based on end user, the Europe organ preservation solution market is segmented into organ transplant centers, hospitals, and specialty clinics. The organ transplant centers segment held the largest market share in 2023.
By country, the Europe organ preservation solution market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe organ preservation solution market share in 2023.
XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, and Accord Healthcare, are among the leading companies operating in the Europe organ preservation solution market.